Voltage-gated sodium channel

Assets acting on this target.

Class
Voltage-gated sodium-channel blocker

Voltage-gated sodium channels are membrane proteins that open briefly when a neuron's membrane depolarizes, allowing a rapid influx of sodium ions that generates the rising phase of the action potential, the electrical signal by which nerve and muscle cells communicate. Because repetitive, high-frequency firing of neurons underlies seizures and certain pain states, drugs that reduce sodium channel availability during periods of sustained depolarization can dampen this excessive activity without abolishing normal, low-frequency signaling. This selective effect on pathologically active cells is called use-dependent or state-dependent block, and it is the shared mechanism behind a large family of anticonvulsant medicines. By stabilizing the inactivated state of the channel, these agents raise the threshold required to sustain rapid firing, which helps prevent the synchronized neuronal discharges characteristic of epileptic seizures. Related channel subtypes also contribute to pain signal transmission in peripheral nerves, making this mechanism relevant to certain neuropathic pain conditions as well. Because sodium channels exist in many tissues, including heart and skeletal muscle, the therapeutic goal is to achieve enough central or peripheral neuronal blockade to control seizures or pain while minimizing effects on channels that maintain normal cardiac rhythm and motor function.

By indication

Related mechanisms

Voltage-gated sodium channel drugs compared

7 drugs, stage by indication
7 drugs acting on Voltage-gated sodium channel: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
Eslicarbazepine acetateAptiomBIAL - Portela, Sumitomo Pharmasmall moleculeApprovedApproved in Epilepsy; Approved in Focal Onset Seizures
FosphenytoinPfizersmall moleculeApprovedApproved in Epilepsy
LamotrigineGlaxoSmithKlinesmall moleculeApprovedApproved in Bipolar Disorder; Approved in Epilepsy; Approved in Lennox-Gastaut Syndrome
Oxcarbazepine (Oxtellar XR)Oxtellar XRSupernus Pharmaceuticalssmall moleculeApprovedApproved in Epilepsy; Approved in Focal Onset Seizures
Oxcarbazepine (Trileptal)TrileptalNovartissmall moleculeApprovedApproved in Epilepsy; Approved in Focal Onset Seizures
RufinamideEisai, Novartissmall moleculeApprovedApproved in Developmental and Epileptic Encephalopathies; Approved in Epilepsy; Approved in Lennox-Gastaut Syndrome
CarisbamateSK Biopharmaceuticals Co., Ltd.small moleculePhase 3Phase 3 in Epilepsy

← all mechanisms